XM-ONE receives US patent protection

AbSorber, part of Allenex group, focusing on antibody detection before transplantation has received US patent protection for its cross match-test XM-ONE®.

The patent, with the title Methods of Donor Specific Crossmatching, was granted by the US Patent and Trademark Office. AbSorber has previously approved patent for XM-ONE® in other regions including the European Union, India, Australia and Canada.

“The fact that our patent was approved in the U.S. is of great value to us. It is a strong confirmation that the product is unique and has a high degree of innovation. Currently we are working hard in collaboration with leading laboratories in the U.S. to establish clinical use of the product”, said Anders Karlsson, CEO Allenex.

XM-ONE®is unique in that it is the first standardized test that can detect antibodies against the cells that line the inside of blood vessels. These endothelial cells are the first point of contact between the transplanted organ and the recipient's immune system. Anti-endothelial cell antibodies have been shown to play a key role in causing post-transplantation rejections. XM-ONE®is CE marked in the EU and FDA cleared in the U.S.

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 19:20 (CET) on October 12, 2011.

For more information please contact:
Anders Karlsson, CEO tel: +4670-918 0010, email: anders.karlsson@allenex.se
Okee Williams, Portfolio & IR Manager tel: +4670-60 053 64, email: okee.williams@allenex.se

Or visit www.allenex.se or www.absorber.se

Allenex is a life science company that develops, manufactures, markets and sells high quality products and services that enables for safer transplantations with better results. Allenex has also a portfolio of associated life science companies. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX).